Early Detection of Ovarian Cancer by Contrast-Enhanced Ultrasound-Targeted Imaging
Abstract
Due to the lack of an early detection test, most cases of OVCA are detected at late stages when the 5-year survival rate is <10%. Transvaginal ultrasound (TVUS) imaging, the currently favored method, it cannot detect OVCA at early stage due to its limited resolution. Tumor related malignant nuclear transformation occurs early in tumor development and leads to the release of Nuclear Matrix Proteins (NMP) into the circulation. Tumor associated neoangiogenesis (TAN) follows malignant nuclear transformation. v 3-integrins and death receptors (DR) 6 are two markers of ovarian TAN expressed by neoangiogenic microvessels. DR6 is also secreted in serum. If the detection limit of TVUS imaging can be enhanced, v 3- integrins expressing microvessels can be an in vivo imaging marker of ovarian TAN and may be used together with serum anti-NMP antibodies and DR6 to detect early stage OVCA. Our overall goal is to improve the TVUS detectability of ovarian TAN vessels at early stage by v 3-integrins targeted contrast enhanced ultrasound (CE-US) molecular imaging. This goal is being achieved by 3 specific aims. The results of aim 1 and aim 2 suggest that CE-US molecular imaging targeting ovarian v 3-integrins can detect ovarian TAN at early stage OVCA in the laying hen model of spontaneous OVCA. Changes in OVCA related CE-US imaging indices are associated with the elevation of serum DR6 levels. Serum prevalence of anti-NMP antibodies is associated with malignant nuclear transformation and can be detected from serum even before the tumor becomes detectable through TVUS imaging.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2012
- Accession Number
- ADA599526
Entities
People
- Animesh Barua
Organizations
- Rush University